Baiardi, Simone
Rossi, Marcello
Mammana, Angela
Appleby, Brian S.
Barria, Marcelo A.
Calì, Ignazio
Gambetti, Pierluigi
Gelpi, Ellen
Giese, Armin
Ghetti, Bernardino
Herms, Jochen
Ladogana, Anna
Mikol, Jacqueline
Pal, Suvankar
Ritchie, Diane L.
Ruf, Viktoria
Windl, Otto
Capellari, Sabina
Parchi, Piero http://orcid.org/0000-0002-9444-9524
Funding for this research was provided by:
Ministero della Salute (Ricerca Corrente)
ministero della salute (Ricerca Corrente)
università di bologna (RFO)
national institutes of health (P01P01AI07774, K99AG068359)
Alma Mater Studiorum - Università di Bologna
Article History
Received: 2 June 2021
Revised: 4 July 2021
Accepted: 14 July 2021
First Online: 29 July 2021
Declarations
:
: Financial interests: BSA received funding through CDC, NIH, Ionis Pharmaceutical and Alector; the other authors declare they have no conflict of interest. Non-financial interests: BSA is member of the board of directors for the CJD Foundation; the other authors declare they have no conflict of interest.
: The study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice guidelines. All medical information was collected as part of national surveillance programs for prion diseases and approved by the local Institutional Review Board for each country/participating center (CE-ISS 09/266, May 2009). All patients’ data and samples were coded to protect their identities. Written informed consent was given by study participants or the next of kin.